Agilent Technologies (A) Expands Its Oncology Diagnostics Reach—Can Growth Keep Up?

Agilent Technologies expanded its oncology diagnostics footprint after European regulators certified its PD-L1 IHC 22C3 pharmDx test as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma, enabling identification of patients who may benefit from Merck’s Keytruda. The approval is Agilent’s eighth CE-marked EU indication for the assay and reinforces a strategy of incremental, high-margin growth through label extensions rather than new product launches. The article also notes Agilent’s June acquisition of Biocare Medical to deepen its clinical pathology capabilities. While the development supports Agilent’s diagnostics growth narrative, the piece is cautious on valuation and competition, highlighting Danaher as a strong rival in pathology and noting that broader life-sciences sentiment and any guidance disappointments could pressure the stock.